STAT3 and non-small cell lung carcinoma: Kim et al. demonstrated a role for the IL-6R/JAK1/STAT3 signaling pathway, leading to STAT3 activation, in de novo resistance to irreversible EGFR-TKIs, such as afatinib, in NSCLC cells with EGFR T790M [72].